 Richard Schulick
Concepts (893)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 162 | 2023 | 732 | 16.790 |
Why?
| | Pancreaticoduodenectomy | 59 | 2023 | 133 | 7.100 |
Why?
| | Adenocarcinoma | 68 | 2023 | 801 | 5.750 |
Why?
| | Carcinoma, Pancreatic Ductal | 47 | 2023 | 212 | 5.690 |
Why?
| | Pancreatectomy | 47 | 2023 | 171 | 4.370 |
Why?
| | Liver Neoplasms | 53 | 2020 | 507 | 4.120 |
Why?
| | Hepatectomy | 36 | 2021 | 119 | 2.250 |
Why?
| | Neuroendocrine Tumors | 12 | 2023 | 85 | 2.140 |
Why?
| | Pancreatic Cyst | 12 | 2022 | 48 | 1.960 |
Why?
| | Laparoscopy | 14 | 2022 | 388 | 1.840 |
Why?
| | General Surgery | 7 | 2021 | 126 | 1.760 |
Why?
| | Common Bile Duct Neoplasms | 9 | 2023 | 24 | 1.740 |
Why?
| | Bile Duct Neoplasms | 13 | 2021 | 56 | 1.730 |
Why?
| | Colorectal Neoplasms | 21 | 2014 | 621 | 1.720 |
Why?
| | Pancreas | 16 | 2023 | 277 | 1.520 |
Why?
| | Neoadjuvant Therapy | 22 | 2023 | 305 | 1.500 |
Why?
| | Carcinoma, Neuroendocrine | 8 | 2023 | 29 | 1.490 |
Why?
| | Humans | 321 | 2023 | 114716 | 1.480 |
Why?
| | Neoplasm Recurrence, Local | 26 | 2023 | 863 | 1.480 |
Why?
| | Neoplasm Staging | 41 | 2023 | 1176 | 1.470 |
Why?
| | Cancer Vaccines | 7 | 2020 | 138 | 1.440 |
Why?
| | Cholangiocarcinoma | 11 | 2012 | 38 | 1.410 |
Why?
| | Survival Rate | 52 | 2023 | 1642 | 1.390 |
Why?
| | Postoperative Complications | 28 | 2023 | 2127 | 1.380 |
Why?
| | Bile Ducts, Intrahepatic | 11 | 2012 | 47 | 1.350 |
Why?
| | Prognosis | 62 | 2023 | 3334 | 1.320 |
Why?
| | Middle Aged | 169 | 2023 | 26746 | 1.290 |
Why?
| | Stomach Neoplasms | 5 | 2014 | 65 | 1.290 |
Why?
| | Aged | 155 | 2023 | 19079 | 1.260 |
Why?
| | Retrospective Studies | 98 | 2023 | 12513 | 1.250 |
Why?
| | Adenocarcinoma, Mucinous | 9 | 2023 | 60 | 1.240 |
Why?
| | Carcinoma, Hepatocellular | 11 | 2016 | 211 | 1.130 |
Why?
| | Female | 208 | 2023 | 59486 | 1.080 |
Why?
| | Male | 192 | 2023 | 55558 | 1.050 |
Why?
| | Pancreatic Fistula | 6 | 2022 | 21 | 1.000 |
Why?
| | Ampulla of Vater | 9 | 2023 | 30 | 0.970 |
Why?
| | Biomarkers, Tumor | 19 | 2022 | 1053 | 0.960 |
Why?
| | Aged, 80 and over | 75 | 2021 | 6346 | 0.960 |
Why?
| | Robotics | 3 | 2015 | 75 | 0.950 |
Why?
| | Neoplasms, Second Primary | 4 | 2019 | 94 | 0.900 |
Why?
| | Minimally Invasive Surgical Procedures | 4 | 2022 | 152 | 0.900 |
Why?
| | Early Detection of Cancer | 6 | 2020 | 328 | 0.900 |
Why?
| | Chemotherapy, Adjuvant | 20 | 2023 | 333 | 0.870 |
Why?
| | Patient Care Team | 7 | 2021 | 517 | 0.860 |
Why?
| | Quality-Adjusted Life Years | 2 | 2013 | 101 | 0.820 |
Why?
| | Internship and Residency | 4 | 2021 | 932 | 0.790 |
Why?
| | Pancreatic Ducts | 6 | 2012 | 69 | 0.780 |
Why?
| | Carcinoma | 5 | 2018 | 198 | 0.770 |
Why?
| | Portal Vein | 6 | 2021 | 76 | 0.750 |
Why?
| | Faculty, Medical | 2 | 2018 | 228 | 0.740 |
Why?
| | Healthcare Disparities | 5 | 2014 | 479 | 0.730 |
Why?
| | Tomography, X-Ray Computed | 23 | 2021 | 2269 | 0.720 |
Why?
| | Listeria monocytogenes | 5 | 2012 | 111 | 0.710 |
Why?
| | Treatment Outcome | 60 | 2023 | 9089 | 0.700 |
Why?
| | Cost-Benefit Analysis | 2 | 2013 | 545 | 0.690 |
Why?
| | Combined Modality Therapy | 17 | 2023 | 1122 | 0.680 |
Why?
| | Adult | 107 | 2022 | 30543 | 0.680 |
Why?
| | Stents | 5 | 2011 | 475 | 0.680 |
Why?
| | Follow-Up Studies | 32 | 2021 | 4420 | 0.650 |
Why?
| | Survival Analysis | 27 | 2022 | 1218 | 0.650 |
Why?
| | Tumor Microenvironment | 9 | 2022 | 433 | 0.650 |
Why?
| | Colonic Neoplasms | 8 | 2020 | 221 | 0.640 |
Why?
| | Pancreatic Diseases | 7 | 2019 | 64 | 0.640 |
Why?
| | Proportional Hazards Models | 20 | 2023 | 1080 | 0.640 |
Why?
| | Duodenal Neoplasms | 3 | 2023 | 19 | 0.630 |
Why?
| | Immunotherapy | 12 | 2022 | 475 | 0.620 |
Why?
| | Lymphatic Metastasis | 22 | 2018 | 280 | 0.600 |
Why?
| | Mentors | 3 | 2021 | 156 | 0.600 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2018 | 29 | 0.590 |
Why?
| | Leadership | 2 | 2018 | 292 | 0.590 |
Why?
| | Vascular Surgical Procedures | 5 | 2021 | 257 | 0.570 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2008 | 43 | 0.570 |
Why?
| | Hospitals | 3 | 2019 | 580 | 0.570 |
Why?
| | Lung Neoplasms | 8 | 2023 | 2199 | 0.550 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 89 | 0.540 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 13 | 2023 | 1361 | 0.540 |
Why?
| | Antineoplastic Agents | 11 | 2021 | 1895 | 0.540 |
Why?
| | Adrenalectomy | 2 | 2006 | 60 | 0.530 |
Why?
| | Cholecystectomy | 4 | 2014 | 45 | 0.520 |
Why?
| | Education, Medical, Continuing | 2 | 2015 | 118 | 0.510 |
Why?
| | Carcinoma, Papillary | 6 | 2017 | 73 | 0.510 |
Why?
| | Quality Assurance, Health Care | 2 | 2015 | 311 | 0.490 |
Why?
| | Benchmarking | 3 | 2021 | 161 | 0.490 |
Why?
| | Fellowships and Scholarships | 2 | 2018 | 227 | 0.490 |
Why?
| | Biomedical Research | 2 | 2013 | 585 | 0.480 |
Why?
| | Cholelithiasis | 1 | 2014 | 31 | 0.480 |
Why?
| | Learning Curve | 1 | 2015 | 63 | 0.480 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2014 | 17 | 0.470 |
Why?
| | Bile Ducts, Extrahepatic | 3 | 2012 | 24 | 0.470 |
Why?
| | Lymphedema | 1 | 2014 | 20 | 0.470 |
Why?
| | Adenoma | 5 | 2020 | 189 | 0.470 |
Why?
| | Cyclophosphamide | 5 | 2020 | 217 | 0.460 |
Why?
| | Mesenteric Veins | 3 | 2021 | 9 | 0.460 |
Why?
| | Esophageal Neoplasms | 4 | 2023 | 273 | 0.460 |
Why?
| | Pheochromocytoma | 3 | 2013 | 54 | 0.460 |
Why?
| | SEER Program | 11 | 2011 | 196 | 0.450 |
Why?
| | Genetic Predisposition to Disease | 7 | 2018 | 2099 | 0.450 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2014 | 100 | 0.450 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2013 | 81 | 0.450 |
Why?
| | Thrombelastography | 3 | 2020 | 175 | 0.440 |
Why?
| | Practice Patterns, Physicians' | 8 | 2021 | 1178 | 0.440 |
Why?
| | Liver Neoplasms, Experimental | 4 | 2014 | 26 | 0.440 |
Why?
| | Catheter Ablation | 11 | 2012 | 291 | 0.440 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 95 | 0.440 |
Why?
| | T-Lymphocytes, Regulatory | 6 | 2022 | 342 | 0.440 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 2 | 2016 | 180 | 0.440 |
Why?
| | Neoplasm Invasiveness | 20 | 2020 | 445 | 0.440 |
Why?
| | Risk Assessment | 19 | 2020 | 2973 | 0.440 |
Why?
| | Neoplasms | 9 | 2022 | 2105 | 0.440 |
Why?
| | Nomograms | 3 | 2022 | 41 | 0.430 |
Why?
| | Rectal Neoplasms | 5 | 2017 | 121 | 0.410 |
Why?
| | Fibrin Tissue Adhesive | 2 | 2009 | 13 | 0.410 |
Why?
| | Cholangitis, Sclerosing | 4 | 2008 | 66 | 0.400 |
Why?
| | Incidental Findings | 7 | 2021 | 70 | 0.400 |
Why?
| | Diagnosis, Differential | 9 | 2022 | 1340 | 0.400 |
Why?
| | Immunohistochemistry | 20 | 2019 | 1635 | 0.400 |
Why?
| | Research Personnel | 1 | 2013 | 151 | 0.400 |
Why?
| | Kaplan-Meier Estimate | 19 | 2018 | 815 | 0.400 |
Why?
| | Cystadenoma, Serous | 4 | 2020 | 18 | 0.390 |
Why?
| | Palliative Care | 6 | 2012 | 641 | 0.390 |
Why?
| | Carcinoma, Islet Cell | 3 | 2006 | 3 | 0.390 |
Why?
| | Interleukin-2 | 4 | 2007 | 417 | 0.390 |
Why?
| | United States | 34 | 2023 | 12176 | 0.380 |
Why?
| | Cohort Studies | 20 | 2023 | 4899 | 0.380 |
Why?
| | Fluorouracil | 10 | 2016 | 152 | 0.380 |
Why?
| | Sigmoid Neoplasms | 1 | 2011 | 3 | 0.380 |
Why?
| | Vascular Neoplasms | 4 | 2020 | 15 | 0.380 |
Why?
| | Solitary Fibrous Tumors | 1 | 2011 | 3 | 0.380 |
Why?
| | Mice, Inbred BALB C | 12 | 2021 | 1151 | 0.380 |
Why?
| | Hepatic Artery | 5 | 2020 | 48 | 0.370 |
Why?
| | Patient Care Planning | 4 | 2018 | 139 | 0.360 |
Why?
| | Gamma Rays | 2 | 2021 | 48 | 0.360 |
Why?
| | Positron-Emission Tomography | 7 | 2008 | 258 | 0.350 |
Why?
| | Length of Stay | 10 | 2021 | 949 | 0.350 |
Why?
| | Cyst Fluid | 4 | 2022 | 27 | 0.350 |
Why?
| | Predictive Value of Tests | 16 | 2018 | 1795 | 0.350 |
Why?
| | MAP Kinase Kinase 4 | 2 | 2006 | 23 | 0.340 |
Why?
| | Mutation | 11 | 2016 | 3349 | 0.340 |
Why?
| | Lymph Node Excision | 3 | 2010 | 141 | 0.340 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 192 | 0.340 |
Why?
| | Disease-Free Survival | 13 | 2023 | 623 | 0.340 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2023 | 59 | 0.340 |
Why?
| | Integrin alpha2 | 1 | 2009 | 3 | 0.340 |
Why?
| | Cystadenocarcinoma, Mucinous | 3 | 2015 | 14 | 0.330 |
Why?
| | Abdominal Abscess | 2 | 2011 | 24 | 0.330 |
Why?
| | Octreotide | 1 | 2009 | 25 | 0.330 |
Why?
| | Time Factors | 20 | 2021 | 6124 | 0.320 |
Why?
| | Risk Factors | 30 | 2018 | 8626 | 0.320 |
Why?
| | Mice | 27 | 2022 | 14916 | 0.320 |
Why?
| | Adenoma, Islet Cell | 2 | 2006 | 10 | 0.320 |
Why?
| | Robotic Surgical Procedures | 2 | 2021 | 85 | 0.320 |
Why?
| | Klatskin Tumor | 3 | 2021 | 4 | 0.320 |
Why?
| | Adrenal Cortex Neoplasms | 2 | 1999 | 48 | 0.320 |
Why?
| | Chemoradiotherapy | 6 | 2022 | 190 | 0.320 |
Why?
| | Biomarkers | 5 | 2022 | 3414 | 0.310 |
Why?
| | Internationality | 2 | 2020 | 144 | 0.310 |
Why?
| | Lymph Nodes | 7 | 2012 | 423 | 0.310 |
Why?
| | Pain, Postoperative | 2 | 2021 | 191 | 0.310 |
Why?
| | Choledochal Cyst | 1 | 2008 | 17 | 0.300 |
Why?
| | Duodenostomy | 1 | 2007 | 5 | 0.300 |
Why?
| | Jejunostomy | 1 | 2007 | 11 | 0.300 |
Why?
| | Digestive System Surgical Procedures | 3 | 2019 | 90 | 0.290 |
Why?
| | Gallbladder Neoplasms | 4 | 2010 | 11 | 0.290 |
Why?
| | Biliary Tract Surgical Procedures | 3 | 2021 | 21 | 0.290 |
Why?
| | Retroperitoneal Neoplasms | 3 | 2016 | 22 | 0.290 |
Why?
| | Cushing Syndrome | 1 | 2006 | 10 | 0.280 |
Why?
| | Chemoradiotherapy, Adjuvant | 3 | 2017 | 40 | 0.280 |
Why?
| | Liver | 6 | 2020 | 1631 | 0.280 |
Why?
| | Breast Neoplasms | 2 | 2017 | 1868 | 0.280 |
Why?
| | Hyperamylasemia | 2 | 2022 | 3 | 0.280 |
Why?
| | von Hippel-Lindau Disease | 1 | 2006 | 11 | 0.280 |
Why?
| | Anastomosis, Surgical | 4 | 2015 | 136 | 0.270 |
Why?
| | Radiosurgery | 2 | 2020 | 302 | 0.270 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 87 | 0.270 |
Why?
| | Esophagectomy | 2 | 2022 | 111 | 0.270 |
Why?
| | Interdisciplinary Communication | 3 | 2021 | 182 | 0.270 |
Why?
| | DNA Helicases | 3 | 2012 | 134 | 0.270 |
Why?
| | Chemoembolization, Therapeutic | 4 | 2012 | 45 | 0.260 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2006 | 129 | 0.260 |
Why?
| | Cell Proliferation | 8 | 2021 | 2196 | 0.260 |
Why?
| | Protein Kinase Inhibitors | 3 | 2013 | 795 | 0.260 |
Why?
| | Peritoneal Neoplasms | 2 | 2020 | 54 | 0.260 |
Why?
| | Endosonography | 4 | 2018 | 140 | 0.260 |
Why?
| | Carcinoma in Situ | 3 | 2012 | 44 | 0.260 |
Why?
| | Pancreatitis | 3 | 2022 | 107 | 0.260 |
Why?
| | Radiotherapy, Intensity-Modulated | 3 | 2018 | 125 | 0.260 |
Why?
| | Membrane Proteins | 4 | 2021 | 1022 | 0.260 |
Why?
| | Hospital Mortality | 10 | 2020 | 776 | 0.260 |
Why?
| | Animals | 36 | 2022 | 31761 | 0.250 |
Why?
| | Precancerous Conditions | 4 | 2011 | 158 | 0.250 |
Why?
| | Arteries | 2 | 2019 | 247 | 0.250 |
Why?
| | Publishing | 1 | 2007 | 125 | 0.250 |
Why?
| | Genetic Engineering | 1 | 2006 | 80 | 0.250 |
Why?
| | B7-H1 Antigen | 2 | 2018 | 142 | 0.250 |
Why?
| | Quality Improvement | 3 | 2023 | 951 | 0.240 |
Why?
| | Adenocarcinoma, Papillary | 2 | 2016 | 9 | 0.240 |
Why?
| | Biliary Tract Neoplasms | 4 | 2006 | 20 | 0.240 |
Why?
| | Quality of Life | 6 | 2020 | 2357 | 0.240 |
Why?
| | Smad4 Protein | 4 | 2013 | 34 | 0.240 |
Why?
| | T-Lymphocytes, Helper-Inducer | 3 | 1994 | 127 | 0.240 |
Why?
| | Tumor Cells, Cultured | 6 | 2021 | 854 | 0.240 |
Why?
| | Baltimore | 5 | 2018 | 43 | 0.230 |
Why?
| | Gastrectomy | 1 | 2005 | 82 | 0.230 |
Why?
| | Cell Line, Tumor | 12 | 2021 | 2725 | 0.230 |
Why?
| | Prospective Studies | 21 | 2019 | 6216 | 0.230 |
Why?
| | Cystadenoma, Mucinous | 2 | 2015 | 13 | 0.230 |
Why?
| | Reoperation | 6 | 2016 | 514 | 0.220 |
Why?
| | Nuclear Proteins | 4 | 2012 | 592 | 0.220 |
Why?
| | Immunity | 2 | 2021 | 121 | 0.220 |
Why?
| | Metastasectomy | 1 | 2023 | 13 | 0.220 |
Why?
| | Chi-Square Distribution | 8 | 2015 | 494 | 0.220 |
Why?
| | Splenectomy | 3 | 2020 | 51 | 0.210 |
Why?
| | Genes, Tumor Suppressor | 5 | 2011 | 77 | 0.210 |
Why?
| | Proto-Oncogene Proteins | 6 | 2012 | 610 | 0.210 |
Why?
| | T-Lymphocytes | 3 | 2021 | 1745 | 0.210 |
Why?
| | Cytoreduction Surgical Procedures | 2 | 2020 | 38 | 0.210 |
Why?
| | Patient Safety | 3 | 2021 | 278 | 0.210 |
Why?
| | Ephrin-B2 | 2 | 2021 | 36 | 0.210 |
Why?
| | Benzamides | 3 | 2008 | 169 | 0.210 |
Why?
| | Immunologic Factors | 2 | 2018 | 220 | 0.210 |
Why?
| | STAT3 Transcription Factor | 2 | 2022 | 173 | 0.210 |
Why?
| | Radiotherapy, Adjuvant | 9 | 2016 | 182 | 0.210 |
Why?
| | Magnetic Resonance Imaging | 8 | 2021 | 3031 | 0.200 |
Why?
| | Incidence | 7 | 2019 | 2312 | 0.200 |
Why?
| | Multivariate Analysis | 9 | 2016 | 1435 | 0.200 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 2 | 2012 | 8 | 0.200 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 15 | 0.200 |
Why?
| | Lymphocytes | 2 | 2020 | 332 | 0.200 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 21 | 0.200 |
Why?
| | Fibrosis | 3 | 2021 | 453 | 0.200 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 34 | 0.200 |
Why?
| | Carcinoembryonic Antigen | 5 | 2015 | 37 | 0.190 |
Why?
| | Disease Progression | 8 | 2022 | 2384 | 0.190 |
Why?
| | Sarcoma | 2 | 2016 | 138 | 0.190 |
Why?
| | Liver Transplantation | 5 | 2012 | 706 | 0.190 |
Why?
| | Melanoma | 2 | 2022 | 629 | 0.190 |
Why?
| | Quinazolines | 3 | 2013 | 243 | 0.190 |
Why?
| | Paternalism | 1 | 2021 | 4 | 0.190 |
Why?
| | Referral and Consultation | 3 | 2021 | 632 | 0.190 |
Why?
| | Employment | 1 | 2022 | 138 | 0.190 |
Why?
| | Feasibility Studies | 5 | 2020 | 737 | 0.190 |
Why?
| | Communication | 2 | 2021 | 747 | 0.190 |
Why?
| | Recombinant Proteins | 2 | 2006 | 1233 | 0.190 |
Why?
| | Hospitals, Teaching | 3 | 2018 | 102 | 0.190 |
Why?
| | Pancreatitis, Chronic | 2 | 2020 | 40 | 0.190 |
Why?
| | Gastroenterology | 1 | 2023 | 159 | 0.190 |
Why?
| | ADAM10 Protein | 1 | 2021 | 28 | 0.180 |
Why?
| | Antineoplastic Agents, Alkylating | 3 | 2020 | 68 | 0.180 |
Why?
| | Serotonin | 3 | 2012 | 291 | 0.180 |
Why?
| | Access to Information | 1 | 2021 | 47 | 0.180 |
Why?
| | Oxycodone | 1 | 2021 | 44 | 0.180 |
Why?
| | Tumor Burden | 6 | 2022 | 261 | 0.180 |
Why?
| | Burns, Electric | 1 | 2020 | 20 | 0.180 |
Why?
| | Comprehension | 1 | 2022 | 155 | 0.180 |
Why?
| | Tattooing | 2 | 2010 | 11 | 0.180 |
Why?
| | Mice, Inbred C57BL | 8 | 2021 | 4710 | 0.180 |
Why?
| | Checklist | 1 | 2021 | 83 | 0.180 |
Why?
| | Organ Transplantation | 1 | 2023 | 159 | 0.180 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 73 | 0.180 |
Why?
| | Sarcopenia | 2 | 2012 | 63 | 0.180 |
Why?
| | Operating Rooms | 1 | 2021 | 87 | 0.180 |
Why?
| | Algorithms | 2 | 2019 | 1468 | 0.180 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2022 | 155 | 0.180 |
Why?
| | Oligonucleotides, Antisense | 1 | 2020 | 100 | 0.180 |
Why?
| | Adolescent | 21 | 2022 | 17808 | 0.180 |
Why?
| | Killer Cells, Natural | 2 | 2017 | 382 | 0.180 |
Why?
| | Pancreaticojejunostomy | 1 | 2020 | 5 | 0.180 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2021 | 706 | 0.170 |
Why?
| | Faculty | 1 | 2021 | 130 | 0.170 |
Why?
| | Kidney Transplantation | 3 | 1997 | 541 | 0.170 |
Why?
| | Health Literacy | 1 | 2022 | 164 | 0.170 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2020 | 58 | 0.170 |
Why?
| | Adaptor Proteins, Signal Transducing | 3 | 2012 | 368 | 0.170 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2020 | 44 | 0.170 |
Why?
| | Radiation Injuries | 1 | 2021 | 128 | 0.170 |
Why?
| | Preoperative Care | 9 | 2018 | 317 | 0.170 |
Why?
| | Age Factors | 9 | 2022 | 2889 | 0.170 |
Why?
| | Genetic Testing | 3 | 2018 | 379 | 0.170 |
Why?
| | Patient-Centered Care | 2 | 2022 | 474 | 0.170 |
Why?
| | Statistics, Nonparametric | 6 | 2011 | 386 | 0.170 |
Why?
| | Radiology | 1 | 2021 | 140 | 0.170 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 168 | 0.170 |
Why?
| | Career Choice | 2 | 2018 | 177 | 0.160 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 168 | 0.160 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 23 | 0.160 |
Why?
| | Adrenocortical Carcinoma | 1 | 1999 | 47 | 0.160 |
Why?
| | Drug Prescriptions | 1 | 2021 | 239 | 0.160 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 159 | 0.160 |
Why?
| | Neoplasm Proteins | 3 | 2008 | 385 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 152 | 0.160 |
Why?
| | Safety Management | 2 | 2010 | 109 | 0.160 |
Why?
| | ras Proteins | 4 | 2012 | 138 | 0.160 |
Why?
| | Analysis of Variance | 8 | 2013 | 1226 | 0.160 |
Why?
| | Flow Cytometry | 5 | 2019 | 1086 | 0.160 |
Why?
| | Thalidomide | 1 | 2018 | 28 | 0.160 |
Why?
| | Molecular Targeted Therapy | 2 | 2019 | 347 | 0.160 |
Why?
| | Health Resources | 1 | 2019 | 122 | 0.150 |
Why?
| | Europe | 4 | 2021 | 336 | 0.150 |
Why?
| | Job Satisfaction | 2 | 2018 | 168 | 0.150 |
Why?
| | Sentinel Surveillance | 1 | 2018 | 38 | 0.150 |
Why?
| | Immunomodulation | 1 | 2018 | 84 | 0.150 |
Why?
| | Thrombophilia | 1 | 2018 | 66 | 0.150 |
Why?
| | T-Lymphocyte Subsets | 3 | 2018 | 384 | 0.150 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 1994 | 965 | 0.150 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2018 | 70 | 0.150 |
Why?
| | Imatinib Mesylate | 2 | 2008 | 63 | 0.150 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2019 | 117 | 0.150 |
Why?
| | Neutrophils | 3 | 2019 | 1163 | 0.140 |
Why?
| | Patient Compliance | 1 | 2021 | 525 | 0.140 |
Why?
| | Telomere | 2 | 2012 | 202 | 0.140 |
Why?
| | Students, Medical | 1 | 2021 | 262 | 0.140 |
Why?
| | Young Adult | 16 | 2022 | 10462 | 0.140 |
Why?
| | Societies, Medical | 2 | 2018 | 663 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2015 | 195 | 0.140 |
Why?
| | DNA Mutational Analysis | 4 | 2016 | 372 | 0.140 |
Why?
| | Trastuzumab | 1 | 2017 | 89 | 0.140 |
Why?
| | Maryland | 4 | 2013 | 37 | 0.140 |
Why?
| | Hyperglycemia | 1 | 2020 | 292 | 0.140 |
Why?
| | DNA Mismatch Repair | 1 | 2016 | 37 | 0.140 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 39 | 0.140 |
Why?
| | Neoplasm Metastasis | 5 | 2012 | 528 | 0.140 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 30 | 0.140 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 8 | 0.140 |
Why?
| | Organ Sparing Treatments | 1 | 2016 | 31 | 0.130 |
Why?
| | Ki-67 Antigen | 2 | 2013 | 106 | 0.130 |
Why?
| | Cannabis | 1 | 2023 | 384 | 0.130 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2018 | 195 | 0.130 |
Why?
| | Deoxycytidine | 5 | 2017 | 138 | 0.130 |
Why?
| | Radiotherapy | 2 | 2019 | 176 | 0.130 |
Why?
| | Receptors, Immunologic | 1 | 2017 | 201 | 0.130 |
Why?
| | Caregivers | 1 | 2022 | 714 | 0.130 |
Why?
| | Signal Transduction | 8 | 2022 | 4521 | 0.130 |
Why?
| | Neoplasm Grading | 5 | 2016 | 242 | 0.130 |
Why?
| | Viscera | 1 | 2015 | 13 | 0.130 |
Why?
| | Efficiency | 1 | 2016 | 84 | 0.130 |
Why?
| | Decision Making | 2 | 2012 | 781 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2022 | 1147 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2016 | 56 | 0.130 |
Why?
| | Constriction, Pathologic | 4 | 2011 | 208 | 0.130 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 25 | 0.130 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2008 | 398 | 0.130 |
Why?
| | Logistic Models | 5 | 2016 | 1843 | 0.130 |
Why?
| | Hepatitis | 2 | 2006 | 45 | 0.130 |
Why?
| | MicroRNAs | 2 | 2012 | 601 | 0.130 |
Why?
| | Cholestasis | 3 | 2011 | 224 | 0.130 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 973 | 0.130 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 773 | 0.130 |
Why?
| | Piperazines | 2 | 2008 | 311 | 0.120 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 354 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 340 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 2 | 2012 | 513 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 332 | 0.120 |
Why?
| | Antimetabolites, Antineoplastic | 3 | 2010 | 82 | 0.120 |
Why?
| | Leucovorin | 1 | 2014 | 43 | 0.120 |
Why?
| | Spleen | 1 | 2016 | 484 | 0.120 |
Why?
| | Metabolomics | 1 | 2019 | 527 | 0.120 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 5 | 2016 | 229 | 0.120 |
Why?
| | Pyrimidines | 2 | 2008 | 378 | 0.120 |
Why?
| | Perioperative Period | 2 | 2011 | 49 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2022 | 761 | 0.120 |
Why?
| | Vitamin B Complex | 1 | 2014 | 38 | 0.120 |
Why?
| | Capecitabine | 4 | 2017 | 45 | 0.120 |
Why?
| | Genome | 2 | 2016 | 272 | 0.120 |
Why?
| | Electronic Health Records | 1 | 2021 | 801 | 0.120 |
Why?
| | Immunoglobulins | 1 | 2014 | 143 | 0.120 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 46 | 0.120 |
Why?
| | Cooperative Behavior | 1 | 2016 | 381 | 0.110 |
Why?
| | Exome | 2 | 2011 | 200 | 0.110 |
Why?
| | Mitotic Index | 1 | 2013 | 26 | 0.110 |
Why?
| | Colectomy | 2 | 2012 | 86 | 0.110 |
Why?
| | Cystadenoma | 1 | 2013 | 3 | 0.110 |
Why?
| | Acinar Cells | 1 | 2013 | 11 | 0.110 |
Why?
| | Pancreas, Exocrine | 1 | 2013 | 8 | 0.110 |
Why?
| | Surveys and Questionnaires | 6 | 2022 | 4622 | 0.110 |
Why?
| | Graft Rejection | 2 | 1994 | 516 | 0.110 |
Why?
| | Survivors | 2 | 2015 | 411 | 0.110 |
Why?
| | Immunosuppressive Agents | 2 | 1997 | 647 | 0.110 |
Why?
| | Venous Thrombosis | 1 | 2015 | 140 | 0.110 |
Why?
| | Cell Movement | 3 | 2022 | 867 | 0.110 |
Why?
| | Interpersonal Relations | 1 | 2016 | 341 | 0.110 |
Why?
| | Databases, Factual | 6 | 2016 | 1126 | 0.110 |
Why?
| | DNA Methylation | 4 | 2008 | 496 | 0.110 |
Why?
| | Isoantigens | 1 | 1993 | 18 | 0.110 |
Why?
| | Enzyme Precursors | 1 | 2013 | 15 | 0.110 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2013 | 154 | 0.110 |
Why?
| | Protein C | 1 | 2013 | 45 | 0.100 |
Why?
| | Fluorodeoxyglucose F18 | 3 | 2008 | 113 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 2 | 2011 | 282 | 0.100 |
Why?
| | Radiopharmaceuticals | 3 | 2008 | 157 | 0.100 |
Why?
| | Psoas Muscles | 1 | 2012 | 5 | 0.100 |
Why?
| | Cholangiography | 3 | 2007 | 16 | 0.100 |
Why?
| | Japan | 2 | 2023 | 87 | 0.100 |
Why?
| | Mice, Nude | 5 | 2020 | 635 | 0.100 |
Why?
| | Tissue Array Analysis | 5 | 2011 | 50 | 0.100 |
Why?
| | Interferon-gamma | 4 | 2011 | 722 | 0.100 |
Why?
| | Safety | 1 | 2014 | 297 | 0.100 |
Why?
| | Biliopancreatic Diversion | 1 | 2012 | 1 | 0.100 |
Why?
| | Hemangioma | 1 | 2012 | 41 | 0.100 |
Why?
| | Liver Cirrhosis | 3 | 2008 | 228 | 0.100 |
Why?
| | Carcinoma, Large Cell | 1 | 2012 | 14 | 0.100 |
Why?
| | Metoclopramide | 1 | 2012 | 16 | 0.100 |
Why?
| | Ataxia Telangiectasia | 1 | 2011 | 17 | 0.100 |
Why?
| | Papilloma, Intraductal | 1 | 2011 | 3 | 0.100 |
Why?
| | Opioid-Related Disorders | 1 | 2019 | 413 | 0.100 |
Why?
| | Radiography | 5 | 2016 | 811 | 0.100 |
Why?
| | Biopsy, Needle | 3 | 2011 | 181 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2006 | 1134 | 0.100 |
Why?
| | Glycolipids | 1 | 2012 | 35 | 0.100 |
Why?
| | Biological Therapy | 1 | 2012 | 27 | 0.100 |
Why?
| | Loss of Heterozygosity | 1 | 2012 | 40 | 0.100 |
Why?
| | Comorbidity | 5 | 2022 | 1449 | 0.100 |
Why?
| | Silk | 1 | 2011 | 1 | 0.100 |
Why?
| | Odds Ratio | 5 | 2016 | 954 | 0.100 |
Why?
| | Paraganglioma, Extra-Adrenal | 1 | 2011 | 6 | 0.100 |
Why?
| | Hyalin | 1 | 2011 | 5 | 0.100 |
Why?
| | Shock, Cardiogenic | 1 | 2012 | 53 | 0.100 |
Why?
| | Cysts | 1 | 2012 | 93 | 0.100 |
Why?
| | X Chromosome Inactivation | 2 | 2013 | 21 | 0.100 |
Why?
| | Injections, Intra-Arterial | 1 | 2011 | 25 | 0.100 |
Why?
| | Hepatic Duct, Common | 1 | 2011 | 5 | 0.100 |
Why?
| | Gentamicins | 1 | 2011 | 42 | 0.100 |
Why?
| | Ovarian Neoplasms | 2 | 2007 | 388 | 0.100 |
Why?
| | Carcinoma, Small Cell | 1 | 2012 | 158 | 0.100 |
Why?
| | Point Mutation | 1 | 2012 | 216 | 0.100 |
Why?
| | Carcinoid Tumor | 1 | 2011 | 25 | 0.100 |
Why?
| | Sutures | 1 | 2011 | 50 | 0.100 |
Why?
| | Transcriptome | 1 | 2016 | 727 | 0.090 |
Why?
| | Registries | 4 | 2012 | 1759 | 0.090 |
Why?
| | Costs and Cost Analysis | 2 | 2022 | 195 | 0.090 |
Why?
| | Blood Coagulation | 1 | 2013 | 217 | 0.090 |
Why?
| | Choice Behavior | 1 | 2012 | 154 | 0.090 |
Why?
| | Patient Selection | 3 | 2011 | 641 | 0.090 |
Why?
| | Neoplasm Transplantation | 3 | 2020 | 232 | 0.090 |
Why?
| | Axons | 1 | 2012 | 177 | 0.090 |
Why?
| | Gene Expression | 3 | 2019 | 1420 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1393 | 0.090 |
Why?
| | Drainage | 2 | 2008 | 151 | 0.090 |
Why?
| | Asia | 2 | 2021 | 53 | 0.090 |
Why?
| | Panniculitis, Peritoneal | 1 | 2010 | 1 | 0.090 |
Why?
| | Antigens | 1 | 2012 | 318 | 0.090 |
Why?
| | Embolization, Therapeutic | 1 | 2012 | 177 | 0.090 |
Why?
| | Pandemics | 3 | 2023 | 1319 | 0.090 |
Why?
| | Genital Neoplasms, Female | 1 | 2011 | 70 | 0.090 |
Why?
| | Surgery Department, Hospital | 1 | 2010 | 21 | 0.090 |
Why?
| | Antigens, Neoplasm | 1 | 2011 | 222 | 0.090 |
Why?
| | Sex Factors | 4 | 2022 | 1717 | 0.090 |
Why?
| | Liver Function Tests | 2 | 2007 | 103 | 0.090 |
Why?
| | Mesentery | 1 | 2010 | 53 | 0.090 |
Why?
| | Cadherins | 1 | 2011 | 176 | 0.090 |
Why?
| | Internal-External Control | 1 | 2010 | 66 | 0.090 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2009 | 9 | 0.080 |
Why?
| | Morbidity | 4 | 2012 | 277 | 0.080 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2009 | 27 | 0.080 |
Why?
| | Collagen Type IV | 1 | 2009 | 22 | 0.080 |
Why?
| | Drug Synergism | 3 | 2007 | 316 | 0.080 |
Why?
| | Uncertainty | 1 | 2010 | 96 | 0.080 |
Why?
| | Biofilms | 1 | 2011 | 223 | 0.080 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 275 | 0.080 |
Why?
| | Adenoma, Liver Cell | 1 | 2009 | 1 | 0.080 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 2 | 2006 | 12 | 0.080 |
Why?
| | Hospitals, University | 2 | 2010 | 171 | 0.080 |
Why?
| | Severity of Illness Index | 3 | 2016 | 2538 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2008 | 271 | 0.080 |
Why?
| | Metabolic Syndrome | 1 | 2012 | 323 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2016 | 1214 | 0.080 |
Why?
| | Chyle | 1 | 2008 | 3 | 0.080 |
Why?
| | Academic Medical Centers | 2 | 2012 | 413 | 0.080 |
Why?
| | Suture Techniques | 1 | 2009 | 115 | 0.080 |
Why?
| | Medical Records | 1 | 2009 | 153 | 0.080 |
Why?
| | CA-19-9 Antigen | 3 | 2022 | 14 | 0.080 |
Why?
| | Chylous Ascites | 1 | 2008 | 6 | 0.080 |
Why?
| | Neoplasms, Experimental | 1 | 2009 | 152 | 0.080 |
Why?
| | Genetic Therapy | 1 | 2010 | 257 | 0.080 |
Why?
| | Hepatitis, Viral, Human | 1 | 2008 | 25 | 0.080 |
Why?
| | Laparotomy | 1 | 2008 | 96 | 0.080 |
Why?
| | Annexins | 1 | 2008 | 3 | 0.080 |
Why?
| | DNA-Binding Proteins | 2 | 2011 | 1314 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2011 | 359 | 0.080 |
Why?
| | Antibodies | 2 | 2009 | 371 | 0.080 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 114 | 0.080 |
Why?
| | Cell Cycle Proteins | 1 | 2011 | 552 | 0.070 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 385 | 0.070 |
Why?
| | Erlotinib Hydrochloride | 3 | 2013 | 65 | 0.070 |
Why?
| | Carcinoma, Acinar Cell | 1 | 2007 | 4 | 0.070 |
Why?
| | Models, Statistical | 1 | 2011 | 604 | 0.070 |
Why?
| | Gastroscopy | 1 | 2007 | 18 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2013 | 955 | 0.070 |
Why?
| | Gastric Emptying | 1 | 2007 | 40 | 0.070 |
Why?
| | Mice, Knockout | 3 | 2022 | 2582 | 0.070 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1521 | 0.070 |
Why?
| | Lymphatic Diseases | 1 | 2007 | 17 | 0.070 |
Why?
| | Histiocytosis, Sinus | 1 | 2007 | 7 | 0.070 |
Why?
| | HIV-1 | 1 | 1993 | 768 | 0.070 |
Why?
| | Anus Neoplasms | 1 | 2007 | 24 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2020 | 3542 | 0.070 |
Why?
| | Blood Urea Nitrogen | 1 | 2007 | 51 | 0.070 |
Why?
| | Transaminases | 1 | 2007 | 25 | 0.070 |
Why?
| | Vaccines, Attenuated | 1 | 2007 | 112 | 0.070 |
Why?
| | Pyrroles | 1 | 2008 | 183 | 0.070 |
Why?
| | Blood Loss, Surgical | 1 | 2007 | 84 | 0.070 |
Why?
| | Electrocoagulation | 1 | 2007 | 38 | 0.070 |
Why?
| | Hormones, Ectopic | 1 | 2006 | 2 | 0.070 |
Why?
| | ACTH Syndrome, Ectopic | 1 | 2006 | 2 | 0.070 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2007 | 45 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 254 | 0.070 |
Why?
| | Receptors, Somatostatin | 1 | 2006 | 24 | 0.070 |
Why?
| | International Agencies | 3 | 2011 | 30 | 0.070 |
Why?
| | Operative Time | 2 | 2017 | 106 | 0.070 |
Why?
| | Somatostatin | 1 | 2006 | 52 | 0.070 |
Why?
| | Albumins | 1 | 2007 | 89 | 0.070 |
Why?
| | Thymidylate Synthase | 1 | 2006 | 11 | 0.070 |
Why?
| | Cyclooxygenase 2 | 1 | 2007 | 164 | 0.070 |
Why?
| | Adrenal Cortex | 1 | 2006 | 32 | 0.070 |
Why?
| | Patient Readmission | 1 | 2012 | 608 | 0.070 |
Why?
| | Cell Differentiation | 1 | 2013 | 1699 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2011 | 689 | 0.070 |
Why?
| | Lymphocyte Activation | 2 | 2005 | 1044 | 0.070 |
Why?
| | Cytoskeletal Proteins | 1 | 2007 | 145 | 0.070 |
Why?
| | Pilot Projects | 3 | 2023 | 1370 | 0.070 |
Why?
| | Exonucleases | 1 | 2006 | 8 | 0.070 |
Why?
| | Dendritic Cells | 1 | 2009 | 436 | 0.070 |
Why?
| | Apoptosis | 4 | 2021 | 2369 | 0.070 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 268 | 0.070 |
Why?
| | Indoles | 1 | 2008 | 306 | 0.070 |
Why?
| | Membrane Glycoproteins | 2 | 2006 | 429 | 0.070 |
Why?
| | Proteomics | 2 | 2008 | 843 | 0.060 |
Why?
| | Organizational Culture | 2 | 2021 | 119 | 0.060 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2007 | 198 | 0.060 |
Why?
| | Transcriptional Elongation Factors | 1 | 2006 | 32 | 0.060 |
Why?
| | Paraganglioma | 1 | 2006 | 47 | 0.060 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2006 | 133 | 0.060 |
Why?
| | B7-1 Antigen | 1 | 2005 | 54 | 0.060 |
Why?
| | Carcinoma, Renal Cell | 1 | 2007 | 173 | 0.060 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 52 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2008 | 560 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 224 | 0.060 |
Why?
| | Hospital Costs | 1 | 2005 | 103 | 0.060 |
Why?
| | Case-Control Studies | 4 | 2018 | 3004 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2007 | 299 | 0.060 |
Why?
| | Proteome | 1 | 2008 | 339 | 0.060 |
Why?
| | Postoperative Period | 2 | 2020 | 289 | 0.060 |
Why?
| | Child | 6 | 2009 | 18352 | 0.060 |
Why?
| | Galectin 3 | 1 | 2004 | 18 | 0.060 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 994 | 0.060 |
Why?
| | Epigenesis, Genetic | 1 | 2008 | 521 | 0.060 |
Why?
| | Periodicals as Topic | 1 | 2007 | 181 | 0.060 |
Why?
| | Mass Screening | 2 | 2010 | 1003 | 0.060 |
Why?
| | Th1 Cells | 1 | 2005 | 123 | 0.060 |
Why?
| | Canada | 2 | 2018 | 322 | 0.060 |
Why?
| | Celiac Artery | 2 | 2020 | 9 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 4 | 1985 | 108 | 0.060 |
Why?
| | Camptothecin | 1 | 2004 | 98 | 0.060 |
Why?
| | Age Distribution | 1 | 2005 | 339 | 0.060 |
Why?
| | Neuropilin-1 | 1 | 2004 | 9 | 0.060 |
Why?
| | Mesenteric Artery, Superior | 2 | 2020 | 12 | 0.060 |
Why?
| | Probability | 1 | 2005 | 291 | 0.060 |
Why?
| | Sex Distribution | 1 | 2005 | 335 | 0.060 |
Why?
| | Immunotherapy, Adoptive | 1 | 2006 | 184 | 0.060 |
Why?
| | Pyridines | 1 | 2007 | 425 | 0.060 |
Why?
| | Protein Array Analysis | 1 | 2004 | 59 | 0.060 |
Why?
| | Transcription Factors | 1 | 2011 | 1528 | 0.060 |
Why?
| | Cholecystitis | 1 | 2003 | 17 | 0.060 |
Why?
| | Reproducibility of Results | 4 | 2014 | 2762 | 0.060 |
Why?
| | Genomic Instability | 1 | 2003 | 38 | 0.060 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2003 | 47 | 0.060 |
Why?
| | Cell Communication | 1 | 2005 | 279 | 0.060 |
Why?
| | Microsatellite Repeats | 1 | 2003 | 136 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 333 | 0.050 |
Why?
| | Postoperative Hemorrhage | 1 | 2023 | 75 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 140 | 0.050 |
Why?
| | Head and Neck Neoplasms | 1 | 2007 | 436 | 0.050 |
Why?
| | Saccharomyces cerevisiae | 1 | 2006 | 477 | 0.050 |
Why?
| | Biopsy | 3 | 2013 | 1040 | 0.050 |
Why?
| | Pneumonectomy | 1 | 2023 | 125 | 0.050 |
Why?
| | Health Care Costs | 1 | 2005 | 380 | 0.050 |
Why?
| | Propylamines | 1 | 2022 | 11 | 0.050 |
Why?
| | Prevalence | 2 | 2023 | 2249 | 0.050 |
Why?
| | Chromogranins | 2 | 2012 | 12 | 0.050 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2007 | 584 | 0.050 |
Why?
| | MutL Protein Homolog 1 | 2 | 2016 | 9 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 249 | 0.050 |
Why?
| | Smoking | 1 | 2009 | 1384 | 0.050 |
Why?
| | X-linked Nuclear Protein | 2 | 2012 | 7 | 0.050 |
Why?
| | Co-Repressor Proteins | 2 | 2012 | 13 | 0.050 |
Why?
| | Radiotherapy, Conformal | 2 | 2012 | 68 | 0.050 |
Why?
| | Jaundice | 2 | 2011 | 14 | 0.050 |
Why?
| | Chemokines | 1 | 2022 | 213 | 0.050 |
Why?
| | Electronics | 1 | 2021 | 67 | 0.050 |
Why?
| | Phenotype | 3 | 2015 | 2811 | 0.050 |
Why?
| | Neuropeptides | 1 | 2021 | 65 | 0.050 |
Why?
| | Clone Cells | 2 | 2012 | 248 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2022 | 180 | 0.050 |
Why?
| | Arginase | 1 | 2020 | 27 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2015 | 1690 | 0.050 |
Why?
| | Pedigree | 2 | 2012 | 464 | 0.050 |
Why?
| | Contrast Media | 3 | 2010 | 343 | 0.050 |
Why?
| | Mitochondria | 1 | 2006 | 751 | 0.040 |
Why?
| | Chromatin Assembly and Disassembly | 2 | 2011 | 88 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 120 | 0.040 |
Why?
| | Molecular Chaperones | 2 | 2012 | 157 | 0.040 |
Why?
| | Terminology as Topic | 2 | 2013 | 187 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 7 | 0.040 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2000 | 9 | 0.040 |
Why?
| | Educational Status | 1 | 2022 | 411 | 0.040 |
Why?
| | Portal System | 1 | 2020 | 13 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 81 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2009 | 447 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 64 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 79 | 0.040 |
Why?
| | Macrophage Activation | 1 | 2020 | 164 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 564 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2020 | 65 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2382 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 593 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 292 | 0.040 |
Why?
| | Acute Disease | 1 | 2022 | 912 | 0.040 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2012 | 52 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 342 | 0.040 |
Why?
| | Abdominal Pain | 2 | 2011 | 135 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 249 | 0.040 |
Why?
| | Drug Utilization Review | 1 | 2019 | 57 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 127 | 0.040 |
Why?
| | HIV Infections | 1 | 1993 | 2469 | 0.040 |
Why?
| | Antigens, Differentiation | 2 | 2011 | 80 | 0.040 |
Why?
| | Inflammation | 2 | 2006 | 2481 | 0.040 |
Why?
| | Sequence Analysis, DNA | 2 | 2012 | 728 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2012 | 313 | 0.040 |
Why?
| | Cytokines | 1 | 2006 | 1843 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2013 | 2557 | 0.040 |
Why?
| | Receptors, Purinergic | 2 | 1988 | 20 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 797 | 0.040 |
Why?
| | Organizational Innovation | 2 | 2010 | 133 | 0.040 |
Why?
| | Ketoconazole | 1 | 1997 | 3 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 299 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 535 | 0.040 |
Why?
| | Quality Indicators, Health Care | 2 | 2012 | 287 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 498 | 0.040 |
Why?
| | Immunocompetence | 1 | 1997 | 40 | 0.040 |
Why?
| | Obesity | 1 | 2010 | 2513 | 0.040 |
Why?
| | Up-Regulation | 3 | 2007 | 812 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 296 | 0.040 |
Why?
| | Protein Binding | 2 | 2022 | 1896 | 0.040 |
Why?
| | Ultrasonography | 2 | 2011 | 629 | 0.040 |
Why?
| | Sclerosis | 2 | 2010 | 11 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2019 | 244 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 252 | 0.040 |
Why?
| | Cyclosporine | 1 | 1997 | 161 | 0.040 |
Why?
| | MCF-7 Cells | 1 | 2017 | 105 | 0.040 |
Why?
| | Patient Satisfaction | 2 | 2012 | 583 | 0.040 |
Why?
| | Monocytes | 1 | 2020 | 503 | 0.040 |
Why?
| | Clinical Audit | 1 | 2016 | 12 | 0.040 |
Why?
| | Program Evaluation | 1 | 2021 | 822 | 0.030 |
Why?
| | MutS Homolog 2 Protein | 1 | 2016 | 12 | 0.030 |
Why?
| | Perioperative Care | 1 | 2018 | 126 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2021 | 462 | 0.030 |
Why?
| | Adenosine | 2 | 1988 | 202 | 0.030 |
Why?
| | Microsomes, Liver | 3 | 1985 | 57 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 2016 | 33 | 0.030 |
Why?
| | Metaplasia | 2 | 2006 | 54 | 0.030 |
Why?
| | Giant Cells | 1 | 2016 | 21 | 0.030 |
Why?
| | Margins of Excision | 1 | 2016 | 29 | 0.030 |
Why?
| | Immunoenzyme Techniques | 2 | 2014 | 195 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 633 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 681 | 0.030 |
Why?
| | Pain Management | 1 | 2019 | 289 | 0.030 |
Why?
| | Machine Learning | 1 | 2019 | 318 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 946 | 0.030 |
Why?
| | Gadolinium DTPA | 2 | 2006 | 47 | 0.030 |
Why?
| | Watchful Waiting | 1 | 2016 | 55 | 0.030 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 2 | 2006 | 40 | 0.030 |
Why?
| | Infection Control | 1 | 2016 | 135 | 0.030 |
Why?
| | HCT116 Cells | 2 | 2006 | 71 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2011 | 2791 | 0.030 |
Why?
| | Enzyme Activation | 2 | 2008 | 787 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 825 | 0.030 |
Why?
| | Carbon Tetrachloride | 2 | 1985 | 6 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 897 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 110 | 0.030 |
Why?
| | Vascular Patency | 1 | 2015 | 97 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2016 | 196 | 0.030 |
Why?
| | Patient Transfer | 1 | 2016 | 144 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2006 | 171 | 0.030 |
Why?
| | Weight Loss | 2 | 2011 | 642 | 0.030 |
Why?
| | Medical Oncology | 1 | 2016 | 229 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2018 | 283 | 0.030 |
Why?
| | Phosgene | 2 | 1984 | 6 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 445 | 0.030 |
Why?
| | Drug Eruptions | 1 | 2013 | 26 | 0.030 |
Why?
| | Chromosomes, Human, X | 1 | 2013 | 60 | 0.030 |
Why?
| | Proteins | 2 | 2012 | 912 | 0.030 |
Why?
| | Immunologic Techniques | 1 | 1993 | 39 | 0.030 |
Why?
| | Transfection | 2 | 2006 | 870 | 0.030 |
Why?
| | Diabetes Mellitus | 2 | 2012 | 904 | 0.030 |
Why?
| | Multiple Endocrine Neoplasia Type 1 | 1 | 2012 | 1 | 0.030 |
Why?
| | Influenza A virus | 1 | 1993 | 90 | 0.030 |
Why?
| | HIV Seropositivity | 1 | 1993 | 109 | 0.030 |
Why?
| | Heredity | 1 | 2012 | 12 | 0.030 |
Why?
| | Review Literature as Topic | 1 | 2012 | 61 | 0.030 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2012 | 16 | 0.020 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2011 | 11 | 0.020 |
Why?
| | Laser Capture Microdissection | 1 | 2012 | 23 | 0.020 |
Why?
| | Gene Dosage | 1 | 2012 | 134 | 0.020 |
Why?
| | Codon | 1 | 2012 | 86 | 0.020 |
Why?
| | Xanthines | 2 | 1988 | 15 | 0.020 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 119 | 0.020 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2011 | 63 | 0.020 |
Why?
| | China | 1 | 2012 | 162 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 2012 | 148 | 0.020 |
Why?
| | Periodic Acid-Schiff Reaction | 1 | 2011 | 3 | 0.020 |
Why?
| | Mitosis | 1 | 2012 | 164 | 0.020 |
Why?
| | Cytodiagnosis | 1 | 2011 | 29 | 0.020 |
Why?
| | Oncogene Proteins | 1 | 2011 | 53 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2011 | 133 | 0.020 |
Why?
| | Ablation Techniques | 1 | 2011 | 29 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 543 | 0.020 |
Why?
| | Asymptomatic Diseases | 1 | 2012 | 75 | 0.020 |
Why?
| | Immune Tolerance | 1 | 1993 | 328 | 0.020 |
Why?
| | CTLA-4 Antigen | 1 | 2011 | 77 | 0.020 |
Why?
| | Frozen Sections | 1 | 2011 | 24 | 0.020 |
Why?
| | Down-Regulation | 1 | 2013 | 596 | 0.020 |
Why?
| | Minnesota | 1 | 2011 | 134 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2012 | 284 | 0.020 |
Why?
| | Neprilysin | 1 | 2011 | 47 | 0.020 |
Why?
| | Gene Frequency | 1 | 2012 | 481 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2011 | 127 | 0.020 |
Why?
| | Lung | 1 | 2023 | 3546 | 0.020 |
Why?
| | Treatment Failure | 1 | 2012 | 332 | 0.020 |
Why?
| | Immunologic Memory | 1 | 1993 | 313 | 0.020 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 77 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2011 | 139 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2011 | 123 | 0.020 |
Why?
| | Carcinoma, Ductal | 1 | 2010 | 11 | 0.020 |
Why?
| | Peritoneal Cavity | 1 | 2010 | 23 | 0.020 |
Why?
| | Portugal | 1 | 2010 | 9 | 0.020 |
Why?
| | Personnel Turnover | 1 | 2010 | 27 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2014 | 351 | 0.020 |
Why?
| | Organizational Case Studies | 1 | 2010 | 69 | 0.020 |
Why?
| | Gastric Bypass | 1 | 2011 | 92 | 0.020 |
Why?
| | Genes, p16 | 1 | 2010 | 16 | 0.020 |
Why?
| | Fanconi Anemia | 1 | 2010 | 11 | 0.020 |
Why?
| | Peutz-Jeghers Syndrome | 1 | 2010 | 8 | 0.020 |
Why?
| | Genes, BRCA2 | 1 | 2010 | 24 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2010 | 50 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2011 | 140 | 0.020 |
Why?
| | beta Catenin | 1 | 2011 | 220 | 0.020 |
Why?
| | Attitude to Death | 1 | 2010 | 62 | 0.020 |
Why?
| | Forms and Records Control | 1 | 2009 | 22 | 0.020 |
Why?
| | Professional Practice | 1 | 2009 | 63 | 0.020 |
Why?
| | Diagnosis-Related Groups | 1 | 2009 | 27 | 0.020 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2009 | 52 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2010 | 156 | 0.020 |
Why?
| | Whole-Body Irradiation | 1 | 2009 | 73 | 0.020 |
Why?
| | Rupture, Spontaneous | 1 | 2009 | 16 | 0.020 |
Why?
| | Tamoxifen | 1 | 2010 | 192 | 0.020 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2012 | 240 | 0.020 |
Why?
| | Promoter Regions, Genetic | 2 | 2003 | 1133 | 0.020 |
Why?
| | Genes, p53 | 1 | 2009 | 62 | 0.020 |
Why?
| | Germ-Line Mutation | 1 | 2010 | 130 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2010 | 297 | 0.020 |
Why?
| | Genes, ras | 1 | 2009 | 91 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 330 | 0.020 |
Why?
| | Postoperative Care | 1 | 2010 | 219 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2011 | 554 | 0.020 |
Why?
| | Anticoagulants | 1 | 2013 | 547 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 295 | 0.020 |
Why?
| | Family Health | 1 | 2009 | 194 | 0.020 |
Why?
| | Molecular Probes | 1 | 2008 | 30 | 0.020 |
Why?
| | Nursing Staff, Hospital | 1 | 2010 | 122 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2011 | 440 | 0.020 |
Why?
| | Surgical Wound Infection | 1 | 2011 | 248 | 0.020 |
Why?
| | Hospitalization | 1 | 2016 | 1752 | 0.020 |
Why?
| | Disease Management | 1 | 2012 | 560 | 0.020 |
Why?
| | Claudins | 1 | 2008 | 24 | 0.020 |
Why?
| | Base Sequence | 1 | 2011 | 2118 | 0.020 |
Why?
| | Recurrence | 1 | 2010 | 936 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2008 | 80 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2008 | 354 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 356 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2008 | 309 | 0.020 |
Why?
| | Chronic Disease | 2 | 2003 | 1590 | 0.020 |
Why?
| | Retreatment | 1 | 2007 | 67 | 0.020 |
Why?
| | Population Surveillance | 1 | 2010 | 392 | 0.020 |
Why?
| | Cell Line | 1 | 1993 | 2639 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1773 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4086 | 0.020 |
Why?
| | Evidence-Based Practice | 1 | 2009 | 185 | 0.020 |
Why?
| | Erythrocyte Transfusion | 1 | 2009 | 186 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2007 | 104 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 305 | 0.020 |
Why?
| | Stromal Cells | 1 | 2007 | 96 | 0.020 |
Why?
| | Medicare | 1 | 2012 | 665 | 0.020 |
Why?
| | Macrophages | 1 | 2013 | 1261 | 0.020 |
Why?
| | Tetrahydrofolates | 1 | 2006 | 11 | 0.020 |
Why?
| | Folic Acid Antagonists | 1 | 2006 | 8 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2008 | 201 | 0.020 |
Why?
| | Gallbladder | 1 | 2006 | 14 | 0.020 |
Why?
| | Lymphotoxin beta Receptor | 1 | 2006 | 2 | 0.020 |
Why?
| | Attitude to Health | 1 | 2010 | 406 | 0.020 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2006 | 3 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2010 | 490 | 0.020 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily B | 1 | 2006 | 10 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2006 | 5 | 0.020 |
Why?
| | Concanavalin A | 1 | 2006 | 75 | 0.020 |
Why?
| | Antigens, Ly | 1 | 2006 | 45 | 0.020 |
Why?
| | Claudin-4 | 1 | 2006 | 9 | 0.020 |
Why?
| | 14-3-3 Proteins | 1 | 2006 | 13 | 0.020 |
Why?
| | Overweight | 1 | 2010 | 471 | 0.020 |
Why?
| | Lectins, C-Type | 1 | 2006 | 61 | 0.020 |
Why?
| | Halothane | 1 | 1985 | 5 | 0.020 |
Why?
| | Receptors, Virus | 1 | 2006 | 75 | 0.020 |
Why?
| | Granzymes | 1 | 2006 | 40 | 0.020 |
Why?
| | Antigens, Surface | 1 | 2006 | 146 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2006 | 119 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 157 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 532 | 0.020 |
Why?
| | Homeostasis | 1 | 2009 | 575 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 934 | 0.020 |
Why?
| | Family | 1 | 2009 | 590 | 0.020 |
Why?
| | Inpatients | 1 | 2009 | 378 | 0.020 |
Why?
| | Retroperitoneal Space | 1 | 2005 | 15 | 0.020 |
Why?
| | CA-125 Antigen | 1 | 2005 | 12 | 0.020 |
Why?
| | Solubility | 1 | 2006 | 224 | 0.020 |
Why?
| | Exoribonucleases | 1 | 2006 | 40 | 0.020 |
Why?
| | Heme | 1 | 1985 | 52 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2006 | 139 | 0.020 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2005 | 14 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2011 | 1197 | 0.020 |
Why?
| | Serine Endopeptidases | 1 | 2006 | 102 | 0.020 |
Why?
| | Iodized Oil | 1 | 2005 | 1 | 0.020 |
Why?
| | Epithelium | 1 | 2006 | 297 | 0.020 |
Why?
| | Methotrexate | 1 | 2006 | 227 | 0.020 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2004 | 15 | 0.020 |
Why?
| | bcl-X Protein | 1 | 2004 | 38 | 0.020 |
Why?
| | Janus Kinase 2 | 1 | 2004 | 31 | 0.020 |
Why?
| | Bile | 1 | 2004 | 26 | 0.020 |
Why?
| | Caspases | 1 | 2006 | 245 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 1987 | 446 | 0.010 |
Why?
| | DNA | 1 | 2011 | 1351 | 0.010 |
Why?
| | Biliary Tract Diseases | 1 | 2004 | 32 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2007 | 954 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 931 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2008 | 1988 | 0.010 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 916 | 0.010 |
Why?
| | Histocytological Preparation Techniques | 1 | 2004 | 2 | 0.010 |
Why?
| | Blotting, Western | 1 | 2007 | 1151 | 0.010 |
Why?
| | Radiography, Interventional | 1 | 2005 | 104 | 0.010 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2004 | 49 | 0.010 |
Why?
| | Paraffin Embedding | 1 | 2004 | 21 | 0.010 |
Why?
| | Methyl n-Butyl Ketone | 1 | 1983 | 1 | 0.010 |
Why?
| | Chloroform | 1 | 1983 | 4 | 0.010 |
Why?
| | Phenobarbital | 1 | 1983 | 17 | 0.010 |
Why?
| | Chile | 1 | 2003 | 16 | 0.010 |
Why?
| | Rats | 6 | 1988 | 4943 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 213 | 0.010 |
Why?
| | Ketones | 1 | 1983 | 45 | 0.010 |
Why?
| | Child, Preschool | 2 | 2009 | 9079 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2003 | 293 | 0.010 |
Why?
| | Body Mass Index | 1 | 2010 | 1958 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2009 | 977 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 743 | 0.010 |
Why?
| | Physicians | 1 | 2009 | 772 | 0.010 |
Why?
| | Rats, Inbred Strains | 3 | 1985 | 354 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 1727 | 0.010 |
Why?
| | Fourier Analysis | 1 | 2000 | 39 | 0.010 |
Why?
| | Phylogeny | 1 | 2003 | 794 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 4406 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2003 | 696 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 5035 | 0.010 |
Why?
| | Image Enhancement | 1 | 2000 | 158 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1997 | 42 | 0.010 |
Why?
| | Antimetabolites | 1 | 1997 | 21 | 0.010 |
Why?
| | Infant | 1 | 2009 | 7935 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 1997 | 386 | 0.010 |
Why?
| | Drug Interactions | 1 | 1997 | 340 | 0.010 |
Why?
| | Lymphogranuloma Venereum | 1 | 1951 | 2 | 0.010 |
Why?
| | Neck | 1 | 1951 | 83 | 0.010 |
Why?
| | Phenylisopropyladenosine | 1 | 1987 | 5 | 0.000 |
Why?
| | Chemistry | 1 | 1987 | 38 | 0.000 |
Why?
| | Chemical Phenomena | 1 | 1987 | 80 | 0.000 |
Why?
| | Diglycerides | 1 | 1987 | 54 | 0.000 |
Why?
| | Phosphatidylethanolamines | 1 | 1987 | 66 | 0.000 |
Why?
| | Aniline Compounds | 1 | 1987 | 70 | 0.000 |
Why?
| | Prodrugs | 1 | 1987 | 42 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1988 | 503 | 0.000 |
Why?
| | Electrophoresis | 1 | 1985 | 26 | 0.000 |
Why?
| | Acetylation | 1 | 1985 | 211 | 0.000 |
Why?
| | Fatty Acids | 1 | 1987 | 382 | 0.000 |
Why?
| | Cerebral Cortex | 1 | 1987 | 380 | 0.000 |
Why?
| | Benzphetamine | 1 | 1983 | 1 | 0.000 |
Why?
| | Cell Membrane | 1 | 1987 | 679 | 0.000 |
Why?
| | Chromatography, Ion Exchange | 1 | 1983 | 48 | 0.000 |
Why?
| | Oxidation-Reduction | 1 | 1984 | 927 | 0.000 |
Why?
| | Oxygen | 1 | 1984 | 853 | 0.000 |
Why?
|
|
Schulick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|